Key result
Nonrandomized pharmacoepidemiologic studies evaluating cardioprotective therapies in cardio-oncology should employ target trial emulation and active comparator designs to mitigate inherent biases.
Why the study?
Does SGLT2 inhibitor therapy prevent heart failure in patients receiving anthracycline-containing chemotherapy?
Does SGLT2 inhibitor therapy prevent heart failure in patients receiving anthracycline-containing chemotherapy?
Rigorous methodological frameworks like target trial emulation are crucial for the accurate interpretation of nonrandomized evidence guiding clinical decisions in cardio-oncology.
[Figure: see text]
No takes yet. Share an insight, caveat, or question.
Chatur et al. (2023) conducted an editorial in Anthracycline-induced cardiotoxicity. SGLT2 inhibitors vs. Unexposed to SGLT2 inhibitors was evaluated. Nonrandomized pharmacoepidemiologic studies evaluating cardioprotective therapies in cardio-oncology should employ target trial emulation and active comparator designs to mitigate inherent biases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: